Therefore, further studies are warranted to better understand the role of the EGFR/PAK1 pathway for improving the survival rates in patients with EGFR-mutated NSCLC, even after they have acquired resistance to tyrosine kinase inhibitors. This evidence concerns the gene PAK1 and non-small cell lung carcinoma.